New Data Presented at ESMO 2022 Show Veracyte's Decipher Pro

11.09.2022 - Veracyte, Inc. (Nasdaq: VCYT) announced that new data from a Phase 3 trial of the multi-center, multi-national, randomized STAMPEDE platform protocol confirm the ability of the company’s Decipher Prostate Genomic Classifier to identify men with ... Seite 1

Related Keywords

United States , Gerhardt Attard , Treatment Resistance Research Group , Veracyte Inc , European Society For Medical Oncology , Nasdaq , University College London Cancer Institute , Decipher Prostate Genomic Classifier , European Society , Medical Oncology , Decipher Prostate , Systemic Therapy , Metastatic Prostate Cancer , Drug Efficacy , Veracyte ,